Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

Chad Mire, Joan B. Geisbert, Krystle N. Agans, Benjamin A. Satterfield, Krista M. Versteeg, Elizabeth A. Fritz, Heinz Feldmann, Lisa E. Hensley, Thomas Geisbert

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G). These vaccines have shown 100% efficacy against filovirus infection in nonhuman primates when challenge occurs 28-35 days after a single injection immunization. Here, we examined the ability of a rVSV MARV-GP vaccine to provide protection when challenge occurs more than a year after vaccination. Cynomolgus macaques were immunized with rVSV-MARV-GP and challenged with MARV approximately 14 months after vaccination. Immunization resulted in the vaccine cohort of six animals having anti-MARV GP IgG throughout the pre-challenge period. Following MARV challenge none of the vaccinated animals showed any signs of clinical disease or viremia and all were completely protected from MARV infection. Two unvaccinated control animals exhibited signs consistent with MARV infection and both succumbed. Importantly, these data are the first to show 100% protective efficacy against any high dose filovirus challenge beyond 8 weeks after final vaccination. These findings demonstrate the durability of VSV-based filovirus vaccines.

Original languageEnglish (US)
Article numbere94355
JournalPLoS One
Volume9
Issue number4
DOIs
StatePublished - Apr 23 2014

Fingerprint

Marburg virus
Marburgvirus
Vesiculovirus
Vesicular Stomatitis
Filoviridae
durability
Viruses
Primates
Durability
Vaccines
vaccines
glycoproteins
Glycoproteins
Vaccination
vaccination
Virus Diseases
Immunization
immunization
Animals
Ebolavirus

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. / Mire, Chad; Geisbert, Joan B.; Agans, Krystle N.; Satterfield, Benjamin A.; Versteeg, Krista M.; Fritz, Elizabeth A.; Feldmann, Heinz; Hensley, Lisa E.; Geisbert, Thomas.

In: PLoS One, Vol. 9, No. 4, e94355, 23.04.2014.

Research output: Contribution to journalArticle

Mire, C, Geisbert, JB, Agans, KN, Satterfield, BA, Versteeg, KM, Fritz, EA, Feldmann, H, Hensley, LE & Geisbert, T 2014, 'Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates', PLoS One, vol. 9, no. 4, e94355. https://doi.org/10.1371/journal.pone.0094355
Mire C, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One. 2014 Apr 23;9(4). e94355. https://doi.org/10.1371/journal.pone.0094355
Mire, Chad ; Geisbert, Joan B. ; Agans, Krystle N. ; Satterfield, Benjamin A. ; Versteeg, Krista M. ; Fritz, Elizabeth A. ; Feldmann, Heinz ; Hensley, Lisa E. ; Geisbert, Thomas. / Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. In: PLoS One. 2014 ; Vol. 9, No. 4.
@article{17e87d7ed5a94b08ac31efead9948aad,
title = "Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates",
abstract = "The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G). These vaccines have shown 100{\%} efficacy against filovirus infection in nonhuman primates when challenge occurs 28-35 days after a single injection immunization. Here, we examined the ability of a rVSV MARV-GP vaccine to provide protection when challenge occurs more than a year after vaccination. Cynomolgus macaques were immunized with rVSV-MARV-GP and challenged with MARV approximately 14 months after vaccination. Immunization resulted in the vaccine cohort of six animals having anti-MARV GP IgG throughout the pre-challenge period. Following MARV challenge none of the vaccinated animals showed any signs of clinical disease or viremia and all were completely protected from MARV infection. Two unvaccinated control animals exhibited signs consistent with MARV infection and both succumbed. Importantly, these data are the first to show 100{\%} protective efficacy against any high dose filovirus challenge beyond 8 weeks after final vaccination. These findings demonstrate the durability of VSV-based filovirus vaccines.",
author = "Chad Mire and Geisbert, {Joan B.} and Agans, {Krystle N.} and Satterfield, {Benjamin A.} and Versteeg, {Krista M.} and Fritz, {Elizabeth A.} and Heinz Feldmann and Hensley, {Lisa E.} and Thomas Geisbert",
year = "2014",
month = "4",
day = "23",
doi = "10.1371/journal.pone.0094355",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

AU - Mire, Chad

AU - Geisbert, Joan B.

AU - Agans, Krystle N.

AU - Satterfield, Benjamin A.

AU - Versteeg, Krista M.

AU - Fritz, Elizabeth A.

AU - Feldmann, Heinz

AU - Hensley, Lisa E.

AU - Geisbert, Thomas

PY - 2014/4/23

Y1 - 2014/4/23

N2 - The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G). These vaccines have shown 100% efficacy against filovirus infection in nonhuman primates when challenge occurs 28-35 days after a single injection immunization. Here, we examined the ability of a rVSV MARV-GP vaccine to provide protection when challenge occurs more than a year after vaccination. Cynomolgus macaques were immunized with rVSV-MARV-GP and challenged with MARV approximately 14 months after vaccination. Immunization resulted in the vaccine cohort of six animals having anti-MARV GP IgG throughout the pre-challenge period. Following MARV challenge none of the vaccinated animals showed any signs of clinical disease or viremia and all were completely protected from MARV infection. Two unvaccinated control animals exhibited signs consistent with MARV infection and both succumbed. Importantly, these data are the first to show 100% protective efficacy against any high dose filovirus challenge beyond 8 weeks after final vaccination. These findings demonstrate the durability of VSV-based filovirus vaccines.

AB - The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G). These vaccines have shown 100% efficacy against filovirus infection in nonhuman primates when challenge occurs 28-35 days after a single injection immunization. Here, we examined the ability of a rVSV MARV-GP vaccine to provide protection when challenge occurs more than a year after vaccination. Cynomolgus macaques were immunized with rVSV-MARV-GP and challenged with MARV approximately 14 months after vaccination. Immunization resulted in the vaccine cohort of six animals having anti-MARV GP IgG throughout the pre-challenge period. Following MARV challenge none of the vaccinated animals showed any signs of clinical disease or viremia and all were completely protected from MARV infection. Two unvaccinated control animals exhibited signs consistent with MARV infection and both succumbed. Importantly, these data are the first to show 100% protective efficacy against any high dose filovirus challenge beyond 8 weeks after final vaccination. These findings demonstrate the durability of VSV-based filovirus vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84899744869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899744869&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0094355

DO - 10.1371/journal.pone.0094355

M3 - Article

C2 - 24759889

AN - SCOPUS:84899744869

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e94355

ER -